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Introduction
Myogenic speciﬁ  cation initially takes place in the somites 
of the developing vertebrate embryo and is thenceforth 
reiterated throughout the life of the organism [1]. Th  is 
process will establish and maintain one of the major 
constituents of the body: skeletal muscle. Th   e presence of 
tissue-speciﬁ  c stem cells, the satellite cells, gives adult 
muscle the capacity for extensive regeneration in 
response to trauma and disease [2]. Despite a funda-
mentally diﬀ   erent hormonal and anatomical environ-
ment, muscle regeneration in the adult organism 
recapitulates many aspects of embryonic myogenesis [3]. 
However, the capacity of adult muscle for regeneration 
seems to be limited and repeated degeneration is accom-
panied by increasingly ineﬃ   cient  tissue  reconstitution 
[4]. Since the discovery of the satellite cell 50 years ago, 
research has provided valuable insights into the 
molecular mechanisms that regulate the satellite cell pool 
and ultimately the potential for regenerative myogenesis 
[5,6]. Particularly, a recently discovered subpopulation of 
satellite cells with an extensive capacity for self-renewal 
and the characterized signaling molecules that control 
these cells hold great potential for therapeutic 
manipulation [7,8].
Developmental myogenesis
Skeletal muscle in all vertebrates originates from cells 
found in the mesoderm, one of the three primary germ 
layers [9,10]. Parts of the mesoderm give rise to 
segmented clusters called somites, which are aligned 
along the anterior-posterior axis of the embryo. Th  e 
somites, the paraxial head mesoderm and the prechordal 
mesoderm are the source of primitive myogenic cells, 
most of which are marked by the expression of two 
paired-box (Pax) transcription factors, Pax3 and Pax7. 
Later during development, a subpopulation of these cells 
will diﬀ   er  en  tiate into terminally committed myocytes. 
Th   e embryonic body axes then orient the fusion of these 
cells, generating the ﬁ   rst multinucleated myoﬁ  bers.  In 
several subsequent waves, more embryonic myocytes 
align and fuse into precisely arranged postmitotic muscle 
ﬁ  bers that will give rise to the organism’s skeletal muscle. 
Limb, trunk and some head muscles arise from cells of 
somitic origin, whereas the remainder of the head 
muscles derive from cells of the paraxial head mesoderm 
and the prechordal mesoderm [1,11-15].
Myogenic speciﬁ   cation during development is regu-
lated by signaling factors released from the surrounding 
tissue. Among such factors are sonic hedgehog (Shh), 
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derived bone morphogenetic proteins (BMPs), and 
members of the wingless-type MMTV integration site 
(Wnt) family of proteins, which emanate from both the 
ectoderm and the neural tube [1]. On the genetic level, 
myogenic determination is modulated by Pax3/Pax7 and 
a family of transcription factors known as myogenic 
regulatory factors (MRFs) [6].
In the perinatal period, the niche in between the basal 
lamina and the muscle ﬁ  ber membrane is populated by 
juvenile satellite cells that proliferate extensively. A subset 
of theses cells will remain as quiescent satellite cells in 
the adult organism [16].
Satellite stem cells
With the exception of some head muscles, satellite cells 
in the adult are generally considered to be the progeny of 
Pax3- and Pax7-expressing cells of somitic origin [11-
14,17]. Pax transcription factors are genetic master 
switches that can imprint stem cells towards a myogenic 
fate but repress genes involved in diﬀ  erentiation. All adult 
satellite cells are marked by the expression of Pax7 whereas 
Pax3 is postnatally down  regulated in most muscles [18]. 
Other molecular markers of satellite cells include vascular 
cell adhesion molecule 1 (VCAM-1), c-Met (receptor for 
hepatocyte growth factor), chemokine C-X-C motif 
receptor 4 (CXCR4), M-cadherin, neural cell adhesion 
molecule 1 (NCAM1), forkhead box protein K1 (Foxk1), 
integrin α7β1, CD34, and syndecans 3 and 4 [19].
In adult skeletal muscle only a small subpopulation of 
Pax7-expressing satellite cells derives from a lineage that 
has never expressed myogenic factor 5 (Myf5), a trans-
cription factor belonging to the MRFs. It has been 
demonstrated that these cells are capable of extensive 
self-renewal and can very eﬃ   ciently  repopulate  their 
niche in transplantation experiments into satellite-cell-
depleted muscle. To date, this cell type makes up the 
most primitive and stem-like population that has been 
identiﬁ   ed in adult muscle tissue and these cells are 
therefore referred to as ‘satellite stem cells’. Conversely, a 
cell that expresses Myf5 or is descended from an ancestor 
that expressed this factor once is more prone to 
diﬀ   erentiation and is therefore termed a ‘satellite 
myogenic cell’ [7].
Regenerative myogenesis
Injury of adult muscle causes an inﬂ  ux of inﬂ  ammatory 
cells that remove necrotic debris from the tissue. 
Subsequently, Pax7-expressing satellite cells enter mitosis 
to generate progeny that will go through repeated rounds 
of proliferation and then migrate to the site of damage. A 
high percentage of this progeny will undergo myogenic 
diﬀ  erentiation in order to restore the destroyed muscle 
ﬁ  bers, whereas others will self-renew and, upon complete 
regeneration, repopulate the muscle as satellite stem cells 
[2].
Once activated by muscle injury, proliferating satellite 
cells become myoblasts through upregulation of a MRF 
called myoblast determination protein (MyoD) [18]. 
MyoD drives proliferation by controlling reentry into the 
cell cycle and activates the transcription of muscle-
speciﬁ  c genes [20]. As a last step, downregulation of Pax7 
and upregulation of myogenin primes the myoblasts to 
become myocytes. Th   ese cells are terminally committed, 
exit the cell cycle and fuse with other myoblasts or 
existing ﬁ  bers.  Th  is process will ﬁ   nally repair the 
damaged muscle tissue [6]. Satellite cell self-renewal and 
the transcription factors controlling lineage progression 
during regeneration are thought to be regulated by a 
variety of extrinsic cues [19]. For the remaining part of 
this review, we will focus on these factors.
The satellite cell niche
A stem cell niche is deﬁ   ned as a speciﬁ  c  anatomical 
location that participates in tissue generation, main-
tenance and repair. Stem cells reside in their niche for an 
indeﬁ  nite period and it protects its host from depletion 
or uncontrolled proliferation [21].
Th   e satellite cell niche is exceptionally complex and the 
sources of environmental inﬂ   uences are diverse. For 
instance, satellite cells are often localized in close proxi-
mity to capillaries, which might be a means to eﬃ   ciently 
supply them with signaling factors [22]. Furthermore, 
several cell types, such as ﬁ  broblasts and immune cells, 
can colonize muscle tissue. Th   ese cells secrete cytokines 
that may inﬂ  uence satellite cells [19]. Neural input leads 
to depolarization of the muscle ﬁ  ber, which can aﬀ  ect 
satellite cells through paracrine factors and adhesion 
molecules [23,24].
Th   e basement membrane and the muscle ﬁ  ber 
sarcolemma, in-between which the satellite cell is 
wedged, are the main anatomical hallmarks of its niche. 
Th  e function of the extracellular matrix (ECM) for 
satellite cells during myogenesis is a matter of ongoing 
investigation. It has been documented that certain ECM 
proteins like laminin and collagen are reciprocally 
regulated by ﬁ   bronectin, hyaluronic acid and tenascin 
during muscle regeneration [25]. Fibronectin inhibits the 
diﬀ   erentiation of cultured myoblasts whereas laminin 
promotes it [26,27]. Mice suﬀ   ering from muscular 
dystrophy, which is caused by a null mutation in the 
laminin alpha 2 chain, display dramatic defects in muscle 
regeneration [28]. Furthermore, knockout of the matrix 
modifying enzyme membrane type 1 metalloprotease 
(MT1-MMP) in mice results in impaired skeletal muscle 
recovery after injury [29]. Th  is evidence demonstrates 
that an intact ECM is essential for muscle repair and 
suggests that transitional changes in its composition 
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structural composition, the niche controls satellite cells 
through several signaling molecules that emanate from a 
wide range of sources (Figure 1).
Signaling factors regulating satellite cells
Th   e amount of satellite cells decreases with age, although 
their myogenic potential does not diminish throughout 
the life of the organism [30]. Th  is notion has been 
supported by experiments demonstrating a signiﬁ  cant 
myogenic capacity of satellite cells transplanted from old 
tissue into young muscle. On the other hand, when young 
cells were transplanted into old muscle, they did not 
perform well [31,32]. Furthermore, exposure of old mice 
to serum from young mice dramatically improved their 
regenerative capacity [33]. Taken together, this evidence 
indicates that satellite cells are highly regulated by 
extrinsic cues. Th  e identiﬁ  cation and understanding of 
these factors will open new avenues for the development 
of therapeutic strategies. Drugs with the ability to 
increase or restore the regenerative potential of skeletal 
muscle by boosting satellite cell function or number 
could help to preserve muscle mass in degenerative 
muscular disorders.
Development of biologics for therapeutic 
manipulation of satellite cells
Satellite stem cell transplantation could theoretically be a 
promising approach to restore or enhance the regener-
ative potential of diseased muscle. In reality, such cell-
based approaches face serious limitations, including the 
need to cultivate satellite cells, their incompatibility with 
systemic delivery, and their poor survival following 
intramuscular injection [34]. For these reasons, 
Figure 1. The satellite cell niche and regulatory factors. (a) Fluorescence microscopic image of a mitotic satellite cell (metaphase) on a mouse 
muscle fi  ber. The satellite cell is labeled by the expression of a yellow fl  uorescent protein and DNA is stained in blue. (b) Schematic of the diff  erent 
environmental cues infl  uencing a satellite cell in its niche. FGF, fi  broblast growth factor; HGF, hepatocyte growth factor; IGF, insulin-like growth 
factor; MGF, mechano-growth factor; NO, nitric oxide; TGF, transforming growth factor.
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tion. Th  e existence of numerous physiological factors 
that are involved in the regulation of satellite cells 
provides an opportunity for the development of drugs 
that mimic or interfere with these molecules [18].
Biologic drugs are pharmaceuticals inherently biological 
in nature and manufactured using biotechnology [35]. 
Th   e advantages of biologics over classic small molecular 
compounds are that they harness the same principles 
employed by endogenous proteins: high functional 
speciﬁ   city resulting in a well deﬁ   ned biological eﬀ  ect 
with little or no oﬀ  -target activity [36]. In the following 
sections we discuss some approaches for the rational 
design of biologics mimicking or inhibiting signaling 
molecules that control satellite cell function.
Transforming growth factor-β
An impaired regenerative capacity and chronic inﬂ  am-
ma  tion with hyperplasia of the interstitial connective 
tissue are pathological hallmarks of muscular dystrophy. 
Inﬂ   ammation of dystrophic muscle is dominated by 
macrophages and T lymphocytes that secrete pro-ﬁ  brotic 
cytokines. Th   is causes a gradual development of ﬁ  brosis, 
which hinders muscle regeneration and ultimately leads 
to incomplete functional recovery [37]. Consequently, 
anti-inﬂ  ammatory and immunosuppressive drugs such as 
corticosteroids and cyclosporine are beneﬁ  cial for these 
conditions. However, weight gain and infections are 
common side eﬀ  ects of these pharmaceutical agents [38]. 
Th  is provides a rationale for the development of thera-
peutics that target the molecular pathways involved in 
the ﬁ  brotic muscle pathology more speciﬁ  cally.
Transforming growth factor-β (TGF-β), a cytokine that 
is released by inﬂ  ammatory cells, has become a focus of 
attention in research on such signaling mechanisms [39]. 
Its expression is dramatically increased in muscular 
dystrophy [40]. Stimulation of muscle resident ﬁ  broblasts 
with this factor increases their collagen and ﬁ  bronectin 
production, which results in increased interstitial ﬁ  brosis 
[41-43]. Furthermore, TGF-β stimulates the diﬀ  erentia-
tion of cultured myoblasts into a ﬁ  brogenic cell type [44]. 
Th  is suggests that TGF-β also drives satellite cells into 
this alternative lineage, which would ultimately deplete 
them from muscle and prevent eﬃ   cient  regeneration. 
More  over, an increase in ﬁ  brogenic cells could further 
exacerbate muscle pathology by contributing to tissue 
ﬁ  brosis.
Inhibition of TGF-β or its downstream eﬀ  ectors  by 
large molecule ligand traps and antisense oligo  nucleo-
tides are novel therapeutic approaches being explored 
today [45]. It is promising that some of these therapeutics 
have already been demonstrated to ameliorate muscular 
dystrophy in certain mouse models [46]. Interestingly, a 
recent study has demonstrated a dose-dependent 
requirement of cultured myoblasts for TGF-β. Th  is 
suggests that speciﬁ   c concentrations of TGF-β have 
permissive inﬂ  uences on satellite cells and it raises some 
concerns about the therapeutic window for inhibitors of 
this factor [47].
Myostatin
Myostatin has been demonstrated to be a powerful 
antagonist of muscle growth. Inhibition or genetic abla-
tion of myostatin triggers dramatic increases in skeletal 
muscle mass across many diﬀ  erent species [48]. Th  e  total 
number of muscle ﬁ   bers per muscle is increased in 
myostatin knockout animals [49,50]. Th   is is indicative of 
increased myogenic activity. Furthermore, the application 
of myostatin to cultured myoblasts prevents diﬀ  eren-
tiation by suppressing MRFs. Conversely, silencing of myo-
statin in myoblast culture increases diﬀ  erentiation [51].
Muscle ﬁ  broblasts do express the myostatin receptor at 
high levels and its activation induces their proliferation 
and the secretion of ﬁ   brotic ECM proteins [52]. 
Myostatin inhibition could therefore be a means to 
improve regeneration of dystrophic muscle by reducing 
ﬁ  brosis while, at the same time, promoting the activation 
of satellite cells. Indeed, it has been demonstrated that 
myostatin deﬁ  ciency or systemic application of inhibitory 
antibodies slows down the degeneration in dystrophic 
muscle of mdx mice [53].
Th  e direct relevance of myostatin for satellite cells 
remains a matter of ongoing investigation. It has been 
reported that satellite cells of myostatin-null mice proli-
ferate more in the resting state while the total number of 
satellite cells per muscle ﬁ  ber increases. Further  more, the 
regenerative potential of myostatin knockout muscle 
seems to be superior to the wild-type counterpart [51]. 
Intriguingly, a recent report rebutted that a myostatin 
deﬁ  ciency is beneﬁ  cial for mdx mice and also excluded a 
direct eﬀ  ect of myostatin on satellite cells [54]. Th  is  study 
challenges several previous reports and it will be 
interesting to follow the future debate on this topic.
A number of circulating factors that control myostatin 
activity have been discovered. Among these is follistatin, 
which can function as a potent myostatin antagonist. 
Overexpression of follistatin in mice causes muscle gains 
beyond myostatin inhibition, which suggests that it 
inhibits additional negative regulators of muscle growth 
and/or satellite cells [51]. Similar to lowering myostatin 
levels, delivery of follistatin to dystrophic mice reversed 
muscle pathology and improved strength [55].
Despite the controversy regarding which cell type 
mediates the eﬀ  ects of myostatin on muscle, antagonists 
that target this factor seem to be promising candidates for 
the treatment of several muscular disorders. Future studies 
will have to clarify the potential of myostatin inhibitors for 
direct therapeutic manipulation of satellite cells.
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Insulin-like growth factor 1 (IGF-1) is either secreted by 
the liver as an endocrine hormone or produced locally by 
other tissues where it can act in a paracrine/autocrine 
fashion [56]. Exogenous IGF-1 or genetic overexpression 
results in increased muscle mass and enhanced 
regeneration in mice. Furthermore, IGF-1 levels are 
upregulated in regenerating muscle and hypertrophy 
induced by this factor not only involves an increase in 
protein synthesis but also augments the DNA content of 
muscle [51]. Th   is evidence suggests that IGF-1 supports 
the mobilization of satellite cells for muscle regeneration.
After stimulation, muscle tissue expresses high levels of 
a splice variant of IGF-1, which is termed mechano-
growth factor (MGF) [57]. MGF promotes the prolifera-
tion and inhibits the diﬀ  erentiation of cultured myoblasts 
[58]. Th   e main circulating isoform of IGF-1 has the same 
eﬀ  ect on proliferation but also facilitates diﬀ  erentiation 
[59-61]. Th   is indicates that the paracrine/autocrine 
eﬀ  ects of MGF rather expand the satellite cell pool, while 
other IGF-1 variants are generally activating and allow 
diﬀ  erentiation. In agreement with this idea, addition of a 
synthetic MGF peptide increased the number of desmin-
positive myogenic cells isolated from healthy and 
diseased muscles [62]. However, because desmin is 
expressed by quiescent and activated satellite cells, MGF’s 
potential for a sustained expansion of the satellite cell 
pool remains to be demonstrated [63]. Interestingly, 
mitotically active young muscle has been found to be 
most responsive to MGF, which argues against a direct 
eﬀ  ect on quiescent satellite cells [64].
In summary, there is evidence that both IGF-1 and 
MGF could be used to stimulate satellite cell function 
and proliferation under pathologic conditions. Th  e ﬁ  rst 
recombinant IGF-1 drugs have recently received US Food 
and Drug Administration (FDA) approval for the 
treatment of IGF-1 deﬁ  ciency, and intense eﬀ  orts for the 
expansion of its use in diseases such as sarcopenia, 
muscular dystrophy and amyotrophic lateral sclerosis are 
ongoing [65-67].
Hepatocyte growth factor
Th   e expression of hepatocyte growth factor (HGF) spikes 
during the early phase of muscle regeneration and 
decreases subsequently during regeneration. HGF is 
sequestered in the ECM of skeletal muscle and released 
upon injury. Th   is factor can stimulate the proliferation of 
cultured myoblasts while inhibiting diﬀ  erentiation [2]. In 
agreement with these ﬁ   ndings, the application of 
recombinant HGF to injured muscle slows regeneration 
while increasing the number of activated satellite cells 
[68]. Th   is suggests that HGF serves to activate quiescent 
satellite cells in the immediate phase after injury while 
blocking diﬀ  erentiation. Once the pool of proliferating 
satellite myogenic cells is suﬃ     ciently expanded in the 
later stages of muscle regeneration, HGF levels decline 
and diﬀ   erentiation is initiated. It remains to be 
determined whether treatment with HGF could be used 
to mobilize satellite cells in situations of inactivity, such 
as atrophy or cachexia.
It has been demonstrated that nitric oxide (NO) 
signaling may act upstream of HGF to modulate the 
activation state of satellite cells. NO seems to augment 
active HGF by triggering its release from the ECM 
through metalloproteinases [69]. Furthermore, increased 
levels of NO promotes regeneration of normal and 
dystrophic muscle [70,71]. Th   e delivery of pharmaceutical 
compounds to increase NO signaling in diseased skeletal 
muscle is feasible and candidate drugs are currently being 
investigated [72].
Fibroblast growth factor
Several ﬁ   broblast growth factors (FGFs), particularly 
FGF-6 and FGF-2, have been demonstrated to induce the 
proliferation of cultured myoblasts while inhibiting their 
diﬀ   erentiation [2,73]. Th  is indicates a role for these 
factors in the expansion of the satellite cell compartment. 
For instance, FGF-6 expression is muscle speciﬁ  c and is 
increased during regeneration [74]. However, results 
from studies of injury-challenged muscle in FGF-6-
deﬁ  cient mice are controversial. Some reports demon-
strated impaired regeneration whereas others could not 
conﬁ  rm such eﬀ  ects [74,75].
FGF2 is sequestered in the basement membrane 
surrounding developing and adult myotubes, and 
neutrali  zing antibodies against FGF2 seem to delay or 
prevent muscle regeneration in the immediate period 
after injury [76,77]. Furthermore, FGF2 appears to 
facilitate satellite cell divisions and muscle regeneration 
in dystrophic mice [78]. Moreover, the combined loss of 
the FGF2 and FGF6 genes increases the dystrophic 
pathology in the musculature of mdx mice, whereas the 
transgenic delivery of both factors to damaged muscle 
enhances regeneration [79,80].
Th  erapeutic recombinant FGFs or biologically active 
derivatives could potentially be used to enhance the 
regenerative potential of muscle by increasing satellite 
cell number. However, further studies will have to clarify 
whether FGF treatment leads to the therapeutically 
desirable expansion of the satellite stem cell compartment 
as opposed to the presumably rather transient eﬀ  ects 
caused by an increase in satellite myogenic cells.
Wnt
  Wnt proteins are secreted lipid-modiﬁ  ed glycoproteins that 
act through Frizzled (Fzd) receptors. Mammals harbor 19 
diﬀ  erent wnt and 10 fzd genes. Historically, Wnt signaling 
has been divided into ‘canonical’ β-catenin-dependent 
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path  ways. More recently, this classiﬁ  cation has been un-
dermined and crosstalk between the canonical and non-
canonical pathways has been described [81].
Given the variety of Wnts, it is not surprising that dif-
ferent species can excerpt both inhibitory and per  missive 
eﬀ  ects on myogenic diﬀ  erentiation. For instance, some 
Wnt molecules facilitate myogenesis during regenera  tion 
while others have been demonstrated to drive the diﬀ  er-
entiation of satellite cells into a ﬁ  brotic lineage [82,83].
It has been reported that a temporal switch from 
activation of the Notch pathway to increased Wnt3a 
signaling is required for myogenic lineage progression 
and consequently for eﬀ  ective muscle regeneration. Th  e 
eﬀ  ects of Wnt3a and Notch signaling are mediated by the 
modulation of the common intracellular eﬀ  ector 
glycogen synthase kinase 3β (GSK3β) [84].
A recent study demonstrated that components of the 
noncanonical planar cell polarity (PCP) pathway regulate 
the expansion of satellite stem cells during muscle 
regeneration in concert with Wnt7a. Wnt7a is expressed 
by muscle ﬁ  bers in the immediate period after myocyte 
fusion. Th   is suggests that Wnt7a release is a physiological 
means to expand the satellite stem cell pool after the 
initial phase of myogenesis. In agreement with this 
theory, muscle-injury-challenged Wnt7a-deﬁ  cient  mice 
display a reduced number of satellite stem cells. Further-
more, Wnt7a application enhances the regenera  tive 
capacity of skeletal muscle dramatically [8]. Th  is  demon-
strates conclusively that an expansion of the satellite stem 
cell population is beneﬁ   cial for skeletal muscle 
regeneration and suggests that manipulation of Wnt7a/
PCP signaling could be therapeutically relevant. Future 
studies will have to address the feasibility of recombinant 
Wnt7a, or mimetics of this factor, for the treatment of 
diseases that are accompanied by a disequilibrium in the 
satellite stem cell pool.
Conclusions
Knowledge about the factors that regulate satellite cell 
activity is not only crucial for their direct manipulation 
but will also foster the success of other approaches, such 
as stem cell therapy. Our understanding of the molecular 
mechanisms that control the speciﬁ  cation  and 
diﬀ  erentiation of satellite cells into a postmitotic muscle 
ﬁ   ber has grown tremendously and a complexity far 
beyond expectations has emerged. In parallel, however, 
promising new starting points for the development of 
therapeutics have been discovered and it is only a matter 
of time until this translates into eﬀ  ective  treatment 
options for degenerative muscular diseases.
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